COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,756 Articles (22,502 medRxiv, 8,254 bioRxiv)

Most recent first Previous |  Page 1787: Articles 17861-17870  | Next

Inference on the dynamics of the COVID pandemic from observational data
Bhattacharjee, S., Liao, S., Paul, D., Chaudhuri, S.
10.1101/2021.02.01.21250936 — Posted: 2021-02-03
SARS-CoV-2 transmission from the healthcare setting into the home: a prospective longitudinal cohort study
Craxford, S., Nightingale, J., Ikram, A., Marson, B. A., Kelly, A., Norrish, A., Vijay, A., Astbury, S., Cusin, L., Ashraf, W., Newham, J., Aithal, G., Tighe, P., Ball, J., Tarr, A. W., Urbanowicz, R. A., Valdes, A., Ollivere, B.
10.1101/2021.02.01.21250950 — Posted: 2021-02-03
Multi-modality detection of SARS-CoV-2 in faecal donor samples for transplantation and in asymptomatic emergency surgical admissions
Manzoor, S. E., Zaman, S., Whalley, C. M., Inglis, D., Bosworth, A., Kidd, M., Shabir, S., Quraishi, N., Green, C. A., Iqbal, T. H., Beggs, A. D.
10.1101/2021.02.02.21250934 — Posted: 2021-02-03
Microscopic dynamics modeling unravels the role of asymptomatic virus carriers in SARS-CoV-2 epidemics at the interplay between biological and social factors
Tadic, B., Melnik, R.
10.1101/2021.02.01.21250926 — Posted: 2021-02-03
Changes in Characteristics of Opioid Overdose Death Trends during the COVID-19 Pandemic
DiGennaro, C., Garcia, G.-G., Stringfellow, E., Wakeman, S., Jalali, M. S.
10.1101/2021.02.01.21250781 — Posted: 2021-02-03
Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
Saad-Roy, C. M., Morris, S. E., Metcalf, C. J. E., Mina, M. J., Baker, R. E., Farrar, J., Holmes, E. C., Pybus, O., Graham, A. L., Levin, S. A., Grenfell, B. T., Wagner, C. E.
10.1101/2021.02.01.21250944 — Posted: 2021-02-03
Increased hazard of death in community-tested cases of SARS-CoV-2 Variant of Concern 202012/01
Davies, N. G., Jarvis, C. I., CMMID COVID-19 Working Group, , Edmunds, W. J., Jewell, N. P., Diaz-Ordaz, K., Keogh, R. H.
10.1101/2021.02.01.21250959 — Posted: 2021-02-03
Vaccinating Australia: How long will it take?
Hanly, M. J.
10.1101/2021.02.02.21250979 — Posted: 2021-02-03
Sex disparities and neutralizing antibody durability to SARS-CoV-2 infection in convalescent individuals
Markmann, A. J., Gaillourou, N., Bhowmik, D. R., Hou, Y. J., Lermer, A., Martinez, D. R., Premkumar, L., Root, H., van Duin, D., Napravnik, S., Graham, S. D., Guerra, Q., Raut, R., Petropoulos, C. J., Wrin, T., Cornaby, C., Schmitz, J., Kuruc, J., Weiss, S., Park, Y., Baric, R., de Silva, A. M., Margolis, D. M., Bartelt, L. A.
10.1101/2021.02.01.21250493 — Posted: 2021-02-03
Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial
Lescure, F.-X., Honda, H., Fowler, R. A., Sloane Lazar, J., Shi, G., Wung, P., Patel, N., Hagino, O.
10.1101/2021.02.01.21250769 — Posted: 2021-02-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).